NORWELL, Mass. — In an effort to address a critical workforce pipeline challenge in medical science, the National Organization for Rare Disorders (NORD®) and the Rosenau Family Research Foundation have officially launched the “Rare Research Launchpad: A Career Exploration Series in Rare Disease Research.” This newly available, free, and self-paced online learning initiative is specifically engineered to introduce students and early-career scientists to the complexities of rare disease research while highlighting the vast professional pathways available within the field.
The comprehensive series is hosted on NORD’s established RareEDU® online learning platform and is accessible at no cost to aspiring researchers, undergraduate and graduate students, and early-career trainees. By leveraging real-world case studies centered on cystic fibrosis and Krabbe disease, the curriculum seeks to demystify the journey of biomedical discovery—guiding participants from fundamental laboratory science through the arduous process of translating discoveries into potential therapies. Furthermore, the program outlines the diverse skills, educational experiences, and collaborative career pathways required to make a tangible impact in the rare disease ecosystem.
Developed by NORD in direct collaboration with clinical and scientific researchers from the prestigious NORD® Rare Disease Centers of Excellence Network, the launchpad bridges traditional academic learning with lived experiences. The curriculum thoughtfully weaves together foundational scientific instruction, personal perspectives from families directly affected by rare conditions, and practical career guidance designed to mentor the next wave of innovators. Organizers note that the program is uniquely positioned to reach students who may otherwise have limited exposure to rare disease research or little awareness of the specialized career opportunities waiting for them in academia, biotechnology, and clinical medicine. It also serves as a robust supplemental educational resource for individuals already pursuing advanced degrees in the sciences and medicine.
The timing of the initiative addresses a pressing long-term need within the broader medical and scientific communities. As modern technologies utilized for studying rare and genetic diseases accelerate at a rapid pace, educational leaders emphasize the imperative need to intentionally cultivate and prepare the scientific workforce that will sustain this momentum.
Rebecca Aune, MPA, Director of Education Programs at NORD, underscored the broader implications of the launch during the announcement. As technologies used to study rare and genetic diseases and develop new therapies continue to advance, she noted, the scientific community must actively prepare the next generation of researchers who will carry this vital work forward. According to Aune, the Rare Research Launchpad provides students with an invaluable early look into the discipline, helping them grasp the fundamental skills, hands-on experiences, and professional relationships necessary to forge a career dedicated to advancing science and improving the daily lives of millions of individuals living with rare conditions.
The selection of cystic fibrosis and Krabbe disease as the foundational case studies for the launchpad was a deliberate choice by the curriculum developers. These two conditions offer distinct, highly illustrative examples of both the scientific hurdles and the unique opportunities inherent in researching rare and genetic diseases. Through these lenses, participants are exposed to broader, critical principles spanning genetics, molecular biology, neuroscience, and translational biomedical research.
Moreover, the case studies demonstrate how foundational laboratory science, rigorous clinical expertise, and the lived realities of patients and families collectively inform the trajectory of research and therapeutic innovation. Crucially, cystic fibrosis and Krabbe disease represent two very different points along the modern therapeutic development landscape. Cystic fibrosis has benefited from decades of sustained, dedicated research that has successfully yielded multiple Food and Drug Administration-approved therapies, including advanced treatments that target the underlying cellular mechanism of the disease. In stark contrast, there is currently no FDA-approved therapy specifically indicated to treat Krabbe disease, a severe, inherited neurodegenerative disorder. By examining both conditions side-by-side, participants gain a realistic and comprehensive understanding of both the historic victories rare disease research can achieve and the formidable scientific challenges that remain across the broader medical landscape.
The initiative is made possible through the financial backing of the Rosenau Family Research Foundation, a dedicated NORD Member Organization. Gabriel M. Cohn, MD, MBA, Executive Director and Medical Director of the Foundation, highlighted the foundation’s core mission and the strategic value of investing in human capital. The Rosenau Family Research Foundation remains intensely focused on advancing impactful research capable of meaningfully improving the lives of individuals and families affected by Krabbe disease and cystic fibrosis, Dr. Cohn explained. He added that supporting NORD’s Rare Research Launchpad enables the foundation to directly invest in future scientists, providing them with a concrete, practical understanding of the complex research questions, diverse career paths, and cross-disciplinary collaborations required to advance treatments across the spectrum of more than 10,000 known rare diseases—of which only about 600 currently have an available, approved treatment.
Designed from the ground up to be scalable and dynamic, the Rare Research Launchpad is structured to expand over time. Organizers plan to incorporate additional rare disease research topics in future phases, creating even broader opportunities for student engagement, professional development, and career exploration within the scientific community.
The Rare Research Launchpad is available immediately online through NORD’s RareEDU platform. Participation in the series is entirely free for all interested learners.
About the National Organization for Rare Disorders
Established in 1983, the National Organization for Rare Disorders (NORD®) operates as a leading, independent, and nonpartisan nonprofit organization. Its overarching mission is to dramatically improve the health, well-being, and overall quality of life for the more than 30 million Americans who are estimated to live with rare diseases. Working in active partnership with more than 350 disease-specific member patient organizations and 49 designated NORD Rare Disease Centers of Excellence—which collectively span over 170 prominent academic medical centers, specialized research institutions, and children’s hospitals across the nation—NORD drives vital advancements in patient care, cutting-edge research, public education, and legislative advocacy to build a more equitable and promising future for the rare disease community.
About the Rosenau Family Research Foundation
The Rosenau Family Research Foundation is a recognized 501(c)(3) private family foundation founded in 2008 with a clear vision to improve the lives of individuals and families impacted by Krabbe disease and cystic fibrosis. The foundation achieves its mission through targeted research funding and strategic advocacy efforts. It proudly supports basic, translational, and clinical research initiatives, alongside comprehensive education and awareness campaigns designed to accelerate the development of effective treatments, cures, and newborn screening protocols, while deepening the scientific and public understanding of both conditions. Additional information regarding the foundation and its ongoing initiatives is available on its official website.
